References
- Chong G, Cunningham D. The role of cetuximab in the therapy of previously treated advanced colorectal cancer. Sem Oncol 2005; 32 (6 Suppl 9): S55-8.
- Cunningham D, Humblet Y, Siena S, et al. Cetuximab monothearpy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45.
- Chung KY, Saltz LB. Antibody-Based Therapies for col-orectal cancer. Oncologist 2005; 10: 701–9.
- Herida M, Mary-Krause M, Kaplan R et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 15,21 (18): 3447-53.
- Cooley TP. Non-AIDS-defining cancer in HIV-infected people. Hematol Oncol Clin N Am 2003; 17: 889–99.
- Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. JC0 2006; 24: 1383–8.
- Berretta M, Martellotta F, Spina M, et al. Clinical fea-tures and outcome of colorectal cancer in HIV-infected peo-ple: a GICAT experience [Abstract]. Gastrointestinal Cancers Symposium - Am Soc Clin Oncol GI Meeting, 2005, Abstract # 201.
- Berretta M, Di Benedetto F, Simonelli C, et al Multidisciplinary approach in a HIV/HCV-positive patient with liver metastases by colorectal cancer in the HAART-era. Ann Oncol. 2006; 17 (8): 1333–4.
- Berretta M, Simonelli C, Lleshi A, et al. Oxaliplatin-based chemotherapy in association with highly active antiretro-viral therapy in metastatic colorectal cancer HIV-infected patients. Ann Oncol. 2006; 17 (4): 712–2.
- Andrè T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resis-tant to the same leucovorin and fluorouracil regimen. JC0 1999; 1: 3560–8.
- Andrè T, Louvet C, Maindrault-Goebel F, et al. CPT-11(irinotecan) addition to bimonthly, high dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pre-treated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999; 35 (9): 1343–7.
- Ancelle-Park R. Expanded European AIDS case defini-tion. Lancet 1993; 341: 441.
- Antoniou T, Tseng AL. Interactions between antiretro-virals and antineoplastic drug therapy. Clin Pharmacokinet 2005; 44 (2): 111–45.
- WHO. WHO Handbook for reporting Results of Cancer Treatment. WHO offset publication No.48, Geneva: WHO 1979.
- Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for research and treatment of cancer, National Cancer Institute of the United States, National cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205–16.
- Klapper LN, Kirschbaum MH, Sela M, et al. Biochemical and clinical implications of the ErbB/HER signal-ing network of growth factor receptors. Adv Cancer Res 2000; 77: 25–79.
- Ciardiello F, Tortora G. A novel approach in the treat-ment of cancer: targeting the epidermal growth factor recep-tor. Clin Cancer Res 2001; 7: 2958–70.
- Saltz L, Rubin MS, Hochster HS et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that express epidermal growth fac-tor receptor. Proc Am Soc Clin Oncol 2001; 20: 3a. abstract.
- Saltz LB, Meropol NJ, Loehrer PJ Sr. Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–8.
- International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823–30.
- Biggar RJ. AIDS-related cancers in the era of highly active antiretroviral therapy. Oncology 2001; 15: 439–48.
- Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 37: 1556–64.